We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)

News   Oct 09, 2009

 
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
 
 
 

RELATED ARTICLES

Placental Mitochondria Adapt When Mothers Have Poor Diets or Low Oxygen

News

Using mice to model conditions in the womb, Cambridge researchers have provided new insights on how the placenta regulates how much oxygen and nutrients it transports to babies during challenging pregnancies.

READ MORE

Infrared to Visible Light: A Novel Route to Photodynamic Therapy & Drug Development

News

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

READ MORE

Targeted Photodynamic Therapy Stops Tumor Growth in 70% of Mice

News

A team of scientists has experimentally proved the effectiveness of the formerly suggested "light" method in oncotherapy. In a series of laboratory preclinical tests, the tumor growth stopped in 70% of mice.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE